Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2015

01-04-2015 | Original Article

Clearing the Confusion over Hepatic Encephalopathy After TIPS Creation: Incidence, Prognostic Factors, and Clinical Outcomes

Authors: Leigh C. Casadaban, Ahmad Parvinian, Jeet Minocha, Janesh Lakhoo, Christopher W. Grant, Charles E. Ray Jr., M. Grace Knuttinen, James T. Bui, Ron C. Gaba

Published in: Digestive Diseases and Sciences | Issue 4/2015

Login to get access

Abstract

Purpose

To assess the incidence, prognostic factors, and clinical outcomes of hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) creation.

Materials and Methods

In this single-institution retrospective study, 191 patients (m:f = 114:77, median age 54 years, median Model for End-Stage Liver Disease or MELD score 14) who underwent TIPS creation between 1999 and 2013 were studied. Medical record review was used to identify demographic characteristics, liver disease, procedure, and outcome data. Post-TIPS HE within 30 days was defined by new mental status changes and was graded according to the West Haven classification system. The influence of data parameters on HE occurrence and 90-day mortality was assessed using binary logistic regression.

Results

TIPS was successfully created with hemodynamic success in 99 % of cases. Median final PSG was 7 mmHg. HE incidence within 30 days was 42 % (81/191; 22 % de novo, 12 % stable, and 8 % worsening). Degrees of HE included grade 1 (46 %), grade 2 (29 %), grade 3 (18 %), and grade 4 (7 %). Medical therapy typically addressed HE, and shunt reduction was necessary in only three cases. MELD score (P = 0.020) and age (P = 0.009) were significantly associated with HE development on multivariate analysis. Occurrence of de novo HE post-TIPS did not associate with 90-day mortality (P = 0.400), in contrast to worsening HE (P < 0.001).

Conclusions

The incidence of post-TIPS HE is non-trivial, but symptoms are typically mild and medically managed. HE rates are higher in older patients and those with worse liver function and should be contemplated when counseling on expected TIPS outcomes and post-procedure course.
Literature
1.
go back to reference Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology. 2009;50:2014–2021.CrossRefPubMed Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology. 2009;50:2014–2021.CrossRefPubMed
2.
go back to reference Garcovich M, Zocco MA, Roccarina D, Ponziani FR, Gasbarrini A. Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota. World J Gastroenterol. 2012;18:6693–6700.CrossRefPubMedCentralPubMed Garcovich M, Zocco MA, Roccarina D, Ponziani FR, Gasbarrini A. Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota. World J Gastroenterol. 2012;18:6693–6700.CrossRefPubMedCentralPubMed
4.
go back to reference Garcia-Pagan JC, Di Pascoli M, Caca K, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol. 2013;58:45–50.CrossRefPubMed Garcia-Pagan JC, Di Pascoli M, Caca K, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol. 2013;58:45–50.CrossRefPubMed
5.
go back to reference Boyer TD, Haskal ZJ, American Association for the Study of Liver Disease. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology. 2010;51:306.CrossRefPubMed Boyer TD, Haskal ZJ, American Association for the Study of Liver Disease. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology. 2010;51:306.CrossRefPubMed
6.
go back to reference Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology. 2004;40:629–635.CrossRefPubMed Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology. 2004;40:629–635.CrossRefPubMed
7.
go back to reference Peter P, Andrej Z, Katarina SP, Manca G, Pavel S. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with recurrent variceal hemorrhage. Gastroenterol Res Pract. 2013. doi:10.1155/2013/398172. Peter P, Andrej Z, Katarina SP, Manca G, Pavel S. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with recurrent variceal hemorrhage. Gastroenterol Res Pract. 2013. doi:10.​1155/​2013/​398172.
8.
go back to reference Masson S, Mardini HA, Rose JD, Record CO. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience. QJM. 2008;101:493–501.CrossRefPubMed Masson S, Mardini HA, Rose JD, Record CO. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience. QJM. 2008;101:493–501.CrossRefPubMed
9.
go back to reference Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–2746.CrossRefPubMed Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–2746.CrossRefPubMed
10.
go back to reference Bureau C, Pagan JC, Layrargues GP, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int. 2007;27:742–747.CrossRefPubMed Bureau C, Pagan JC, Layrargues GP, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int. 2007;27:742–747.CrossRefPubMed
11.
go back to reference Tripathi D, Ferguson J, Barkell H, et al. Improved clinical outcome with transjugular intrahepatic portosystemic stent-shunt utilizing polytetrafluoroethylene-covered stents. Eur J Gastroenterol Hepatol. 2006;18:225–232.CrossRefPubMed Tripathi D, Ferguson J, Barkell H, et al. Improved clinical outcome with transjugular intrahepatic portosystemic stent-shunt utilizing polytetrafluoroethylene-covered stents. Eur J Gastroenterol Hepatol. 2006;18:225–232.CrossRefPubMed
12.
go back to reference Mamiya Y, Kanazawa H, Kimura Y, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Hepatol Res. 2004;30:162–168.CrossRefPubMed Mamiya Y, Kanazawa H, Kimura Y, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Hepatol Res. 2004;30:162–168.CrossRefPubMed
13.
go back to reference Dissanayake O, MacNaughton J, Patch D, Morgan MY. Hepatic encephalopathy is a significant predictor of mortality following tips insertion for refractory ascites. J Hepatol. 2013;58:S420–S421.CrossRef Dissanayake O, MacNaughton J, Patch D, Morgan MY. Hepatic encephalopathy is a significant predictor of mortality following tips insertion for refractory ascites. J Hepatol. 2013;58:S420–S421.CrossRef
14.
go back to reference Krajina A, Hulek P, Fejfar T, Valek V. Quality improvement guidelines for transjugular intrahepatic portosystemic shunt (TIPS). Cardiovasc Interv Radiol. 2012;35:1295–1300.CrossRef Krajina A, Hulek P, Fejfar T, Valek V. Quality improvement guidelines for transjugular intrahepatic portosystemic shunt (TIPS). Cardiovasc Interv Radiol. 2012;35:1295–1300.CrossRef
15.
go back to reference Qin JP, Jiang MD, Tang W, et al. Clinical effects and complications of TIPS for portal hypertension due to cirrhosis: a single center. World J Gastroenterol. 2013;19:8085–8092.CrossRefPubMedCentralPubMed Qin JP, Jiang MD, Tang W, et al. Clinical effects and complications of TIPS for portal hypertension due to cirrhosis: a single center. World J Gastroenterol. 2013;19:8085–8092.CrossRefPubMedCentralPubMed
16.
go back to reference Gaba RC, Omene BO, Podczerwinski ES, et al. TIPS for treatment of variceal hemorrhage: clinical outcomes in 128 patients at a single institution over a 12-year period. J Vasc Interv Radiol. 2012;23:227–235.CrossRefPubMed Gaba RC, Omene BO, Podczerwinski ES, et al. TIPS for treatment of variceal hemorrhage: clinical outcomes in 128 patients at a single institution over a 12-year period. J Vasc Interv Radiol. 2012;23:227–235.CrossRefPubMed
17.
go back to reference Nolte W, Wiltfang J, Schindler C, et al. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology. 1998;28:1215–1225.CrossRefPubMed Nolte W, Wiltfang J, Schindler C, et al. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology. 1998;28:1215–1225.CrossRefPubMed
18.
go back to reference Haskal ZJ, Rees CR, Ring EJ, Saxon R, Sacks D, Society of Interventional Radiology Technology Assessment Committee. Reporting standards for transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol. 2003;14:S419–S426.CrossRefPubMed Haskal ZJ, Rees CR, Ring EJ, Saxon R, Sacks D, Society of Interventional Radiology Technology Assessment Committee. Reporting standards for transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol. 2003;14:S419–S426.CrossRefPubMed
19.
go back to reference Sze DY, Hwang GL, Kao JS, et al. Bidirectionally adjustable TIPS reduction by parallel stent and stent-graft deployment. J Vasc Interv Radiol. 2008;19:1653–1658.CrossRefPubMed Sze DY, Hwang GL, Kao JS, et al. Bidirectionally adjustable TIPS reduction by parallel stent and stent-graft deployment. J Vasc Interv Radiol. 2008;19:1653–1658.CrossRefPubMed
22.
go back to reference Zhu JY, Leng XS, Dong N, Qi GY, Du RY. Measurement of liver volume and its clinical significance in cirrhotic portal hypertensive patients. World J Gastroenterol. 1999;5:525–526.PubMed Zhu JY, Leng XS, Dong N, Qi GY, Du RY. Measurement of liver volume and its clinical significance in cirrhotic portal hypertensive patients. World J Gastroenterol. 1999;5:525–526.PubMed
23.
go back to reference Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005;42:674–679.CrossRefPubMed Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005;42:674–679.CrossRefPubMed
24.
go back to reference Tong C, Xu X, Liu C, Zhang T, Qu K. Assessment of liver volume variation to evaluate liver function. Front Med. 2012;6:421–427.CrossRefPubMed Tong C, Xu X, Liu C, Zhang T, Qu K. Assessment of liver volume variation to evaluate liver function. Front Med. 2012;6:421–427.CrossRefPubMed
25.
go back to reference May BJ, Talenfeld AD, Madoff DC. Update on portal vein embolization: evidence-based outcomes, controversies, and novel strategies. J Vasc Interv Radiol. 2013;24:241–254.CrossRefPubMed May BJ, Talenfeld AD, Madoff DC. Update on portal vein embolization: evidence-based outcomes, controversies, and novel strategies. J Vasc Interv Radiol. 2013;24:241–254.CrossRefPubMed
26.
go back to reference Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Gastroenterology. 2001;120:A76–A77.CrossRef Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Gastroenterology. 2001;120:A76–A77.CrossRef
27.
go back to reference Gaba RC, Couture PM, Bui JT, et al. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol. 2013;24:411–420.CrossRefPubMed Gaba RC, Couture PM, Bui JT, et al. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol. 2013;24:411–420.CrossRefPubMed
28.
go back to reference Al Sibae MR, Cappell MS. Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS. Dig Dis Sci. 2011;56:977–987.CrossRefPubMed Al Sibae MR, Cappell MS. Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS. Dig Dis Sci. 2011;56:977–987.CrossRefPubMed
Metadata
Title
Clearing the Confusion over Hepatic Encephalopathy After TIPS Creation: Incidence, Prognostic Factors, and Clinical Outcomes
Authors
Leigh C. Casadaban
Ahmad Parvinian
Jeet Minocha
Janesh Lakhoo
Christopher W. Grant
Charles E. Ray Jr.
M. Grace Knuttinen
James T. Bui
Ron C. Gaba
Publication date
01-04-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3391-0

Other articles of this Issue 4/2015

Digestive Diseases and Sciences 4/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.